Exploring BNCT as a Novel Approach for Metastatic Spinal Tumor Management

first_page Download PDF settings Order Article Reprints Font Type: Arial Georgia Verdana Font Size: Aa Aa Aa Line Spacing:    Column Width:    Background: Open AccessAbstract Exploring BNCT as a Novel Approach for Metastatic Spinal Tumor Management † by Yoshiki FujikawaYoshiki Fujikawa SciProfiles Scilit Preprints.org Google Scholar 1,*, Shinji KawabataShinji Kawabata SciProfiles Scilit Preprints.org Google Scholar 1, Kohei TsujinoKohei Tsujino SciProfiles Scilit Preprints.org Google Scholar 1, Ryo KayamaRyo Kayama SciProfiles Scilit Preprints.org Google Scholar 1, Hideki KashiwagiHideki Kashiwagi SciProfiles Scilit Preprints.org Google Scholar 1, Yusuke FukuoYusuke Fukuo SciProfiles Scilit Preprints.org Google Scholar 1, Ryo HiramatsuRyo Hiramatsu SciProfiles Scilit Preprints.org Google Scholar 1, Takushi TakataTakushi Takata SciProfiles Scilit Preprints.org Google Scholar 2, Hiroki TanakaHiroki Tanaka SciProfiles Scilit Preprints.org Google Scholar 2, Minoru SuzukiMinoru Suzuki SciProfiles Scilit Preprints.org Google Scholar 2, Naonori HuNaonori Hu SciProfiles Scilit Preprints.org Google Scholar 3, Shin-Ichi MiyatakeShin-Ichi Miyatake SciProfiles Scilit Preprints.org Google Scholar 3, Toshihiro TakamiToshihiro Takami SciProfiles Scilit Preprints.org Google Scholar 1 and Masahiko WanibuchiMasahiko Wanibuchi SciProfiles Scilit Preprints.org Google Scholar 1 1 Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan 2 Institute for Integrated Radiation, Nuclear Science, Kyoto University, Kumatori 520-2113, Japan 3 Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan * Author to whom correspondence should be addressed. † Presented at the 4th International Electronic Conference on Cancers, 6–8 March 2024; Available online: https://sciforum.net/event/IECC2024. Proceedings 2024, 100(1), 3; https://doi.org/10.3390/proceedings2024100003 Published: 27 March 2024 Download keyboard_arrow_down Download PDF Download PDF with Cover Download XML Download Epub Versions Notes Keywords: BNCT; metastatic spinal tumor; radiation therapy [Background] Boron neutron capture therapy (BNCT) is a particle beam therapy that enables the precise targeting of tumors at the cellular level. Building on the success observed in nuclear reactors, BNCT exhibits potential as a therapeutic approach for managing invasive brain tumors, including malignant gliomas and high-grade meningiomas. Metastatic spinal tumors have been treated by surgical removal, radiation therapy, and a variety of other multidisciplinary therapies. However, none of them has been successful in overcoming this metastatic disease. This study aimed to assess the efficacy of BNCT in treating metastatic spinal tumor using a mouse model.[Methods] In vitro experiment: neutron irradiation was applied to A549 human lung carcinoma cells with (BNCT group) or without p-boronophenylalanine (BPA) 10 µg Boron/mL for 24 h exposure before irradiation (hot control group) for 0 to 30 min. The cell killing effect was assessed by a colony forming assay. In vivo experiment: an A549 subcutaneous tumor was removed and implanted into the lumbar lamina, where it was partially resected. A few weeks later, metastatic spinal tumor models were successfully established. For the biodistribution of boron, after 2.5, 6, or 24 h of intravenous BPA administration (250 mg/mouse body weight), the metastatic spinal tumor models were sacrificed and the boron concentration of the tumor and each organ measured using Inductively Coupled Plasma Atomic Emission Spectroscopy (ICP-AES).[Results] In vitro neutron experiment: the BNCT group showed a greater cell killing effect than the hot control group. The highest boron accumulation in the tumor was observed at 2.5 h after BPA administration (10.5 µg B/g), and the tumor to normal spinal cord ratio (T/N) was 3.6 and the tumor to blood ratio (T/Bl) was 2.9.[Conclusions] The findings may indicate that BNCT represents an effective approach in the management of metastatic spinal tumor. We will perform an in vivo neutron irradiation experiment on this model to evaluate the effects of BNCT on survival and neurological function. Author ContributionsConceptualization, S.K.; methodology, Y.F. (Yoshiki Fujikawa), K.T., R.K., H.K., Y.F. (Yusuke Fukuo), R.H. and S.K.; validation, Y.F. (Yoshiki Fujikawa) and S.K.; formal analysis, Y.F. (Yoshiki Fujikawa); investigation, Y.F. (Yoshiki Fujikawa); resources, T.T. (Takushi Takata), H.T., N.H. and M.S.; data curation, Y.F. (Yoshiki Fujikawa); writing—original draft preparation, Y.F. (Yoshiki Fujikawa); writing—review and editing, S.K.; visualization, Y.F. (Yoshiki Fujikawa); supervision, S.-I.M. and M.W.; project administration, S.K.; funding acquisition, S.K. and T.T. (Toshihiro Takami). All authors have read and agreed to the published version of the manuscript.FundingThis research was funded by the Japan Society for the Promotion of Science (JSPS) KAKENHI, grant number JP22K09270 to T.T. (Toshihiro.Takami) [Grants-in-Aid for Science Research (C)] and partly by JP23H03024 to S.K. [Grants-in-Aid for Science Research (B)].Institutional Review Board StatementThe study was conducted in accordance with the guidelines of the Declaration of Helsinki and approved by the Animal Use Review Board and Ethical Committee of Osaka Medical and Pharmaceutical University (No. AM2023-019) and the Institute for Integrated Radiation and Nuclear Science, Kyoto University (No. R5032).Informed Consent StatementNot applicable.Data Availability StatementAll data analyzed in this study are available upon reasonable request to the corresponding author. The JMP Pro version 16.2.0. software (SAS, Cary, NC, USA) was used for the statistical analysis.Conflicts of InterestThe authors declare no conflicts of interest.Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Share and Cite MDPI and ACS Style Fujikawa, Y.; Kawabata, S.; Tsujino, K.; Kayama, R.; Kashiwagi, H.; Fukuo, Y.; Hiramatsu, R.; Takata, T.; Tanaka, H.; Suzuki, M.; et al. Exploring BNCT as a Novel Approach for Metastatic Spinal Tumor Management. Proceedings 2024, 100, 3. https://doi.org/10.3390/proceedings2024100003 AMA Style Fujikawa Y, Kawabata S, Tsujino K, Kayama R, Kashiwagi H, Fukuo Y, Hiramatsu R, Takata T, Tanaka H, Suzuki M, et al. Exploring BNCT as a Novel Approach for Metastatic Spinal Tumor Management. Proceedings. 2024; 100(1):3. https://doi.org/10.3390/proceedings2024100003 Chicago/Turabian Style Fujikawa, Yoshiki, Shinji Kawabata, Kohei Tsujino, Ryo Kayama, Hideki Kashiwagi, Yusuke Fukuo, Ryo Hiramatsu, Takushi Takata, Hiroki Tanaka, Minoru Suzuki, and et al. 2024. "Exploring BNCT as a Novel Approach for Metastatic Spinal Tumor Management" Proceedings 100, no. 1: 3. https://doi.org/10.3390/proceedings2024100003 Article Metrics No No Article Access Statistics Multiple requests from the same IP address are counted as one view.